Retrospective Analysis for Long-Term Survivors in advanced non-small cell lung cancer

Not Applicable

• Conditions: on-small Cell Lung Cancer

• Registration Number: JPRN-UMIN000006913
• Lead Sponsor: Kansai Respiratory Clinical Network Research Group

Brief Summary

A total of 335 patients were recruited. Twenty-eight (8.4%) patients survived more than 5 years.Sixty-five and 93 patients received gefitinib as rechallenge and beyond progressive disease (BPD), respec-tively. A statistically significant difference in OS was observed between the patients who underwentgefitinib rechallenge and those who did not rechallenge (median: 1272 days vs. 774 days; p < 0.001), aresult supported by a DTRA. Patients treated with gefitinib BPD also showed a tendency of longer survival.Conclusions: Gefitinib rechallenge and BPD played a central role in long term survival of the patients whoinitially responded to gefitinib.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-12-20
• Study Completion: 2012-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Not provided

Exclusion Criteria

1.patients with curative surgical operation 2.patients with curative radiation therapy

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Overall survival